| 제품명 | Linagliptin |
|---|---|
| CAS 번호 | 668270-12-0 |
| 분자식 | C25H28N8O2 |
| 분자량 | 472.54 g/mol |
| 외관 | 흰색에서 미백색의 결정성 분말 |
| 분석법 (HPLC) | ≥99.0% |
| 건조 손실 | ≤0.5% |
| 소각 잔류물 | ≤0.1% |
| 중금속 | ≤10 ppm |
| 융점 | 196-202°C |
| 특정 회전 | [α]D20 = +50° to +56° (c=1, methanol) |
도움이 필요하신가요? 저희 팀에 문의해 주세요
Linagliptin is the DPP-4 inhibitor that doesn’t need a dose adjustment for kidney or liver function – and that’s a big deal for type 2 diabetes patients who often have comorbidities. Unlike many of its peers, it’s cleared primarily via bile and gut, so it’s a safer bet for long-term use in renally impaired patients. For formulators, that means a competitive edge in a crowded market: you can offer a once-daily, 5 mg tablet that works reliably without the monitoring headaches.
We supply linagliptin as a high-purity, crystalline API that meets or exceeds pharmacopoeial standards. Every batch is rigorously tested and shipped with a full COA, so you can move from development to production with confidence.
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese